Application of a minimally invasive full‐thickness autologous microcolumn skin harvesting device for donor site tissue collection and augmenting wound healing in a porcine wound model Authors: Stephen Smith, Brenda Curtis, Lisa Nicholson, Thomas Koshy, Tyler Max, Brian Prevish, Madeleine Goedegebuure, Gregory Manista, Joshua Tam Published: 2024 ABSTRACT AbstractUsing a 6‐week porcine full‐thickness excisional wound grafting model, we evaluated the Autologous Regeneration of Tissue (ART®) System, a novel skin harvesting device designed to collect autologous full‐thickness autologous microcolumns (FTAM) at 0.5 mm in diameter. The donor skin sites were harvested using the ART® System and compared to split‐thickness skin grafts (STSGs). Recipient sites were divided into three treatment groups: FTAM, STSG and Untreated control. Comparing the FTAM donor sites to the STSG donor sites, we observed significantly faster re‐epithelization by Day 4 (p < 0.05), earlier adnexal structures and rete ridge formation by Week 3, and increased collagen and elastin content by Week 6. We also observed an increased rate of healing at the FTAM donor site whilst limiting donor site morbidity compared to traditional STSG donor sites. Time to recipient site closure was 2.4 weeks for STSG treated, 3.3 weeks for FTAM treated and 4.1 weeks for the Untreated control (p < 0.05). The STSG and FTAM recipient sites reached complete re‐epithelialization by Weeks 4 and 5, respectively which was significantly faster compared to the Untreated control. However, the FTAM recipient site received only 10% of the donor site tissue relative to the recipient site area and the amount of donor site tissue grafted on the STSG recipient sites was 5× more than the FTAM recipient sites. Additionally, the FTAMs harvested by the ART® System augmented recipient wound site healing as a result of ‘epithelial island’ expansion in contrast to Untreated control sites that closed primarily by contracture.Keywords: fractional autologous full‐thickness skin grafting (FFTSG), full‐thickness autologous microcolumns (FTAM), full‐thickness skin model (FTSM), full‐thickness skin tissue micrografts (FTSTC), split‐thickness skin grafts (STSG) INTRODUCTION Autologous skin grafts are generally accepted as the ‘gold standard’ for treating acute and chronic wounds. 1 , 2 , 3 , 4 Autologous skin grafts are superior over allogeneic skin grafts that inevitably undergo graft rejection within the first few weeks of transplantation. 5 , 6 Autologous skin grafting is limited by tissue availability and long‐term, often permanent, donor‐site morbidity, including skin discolouration, scarring, pain and infection. 7 , 8 , 9 Traditional autologous skin grafts include split‐thickness skin grafts (STSGs) and full‐thickness skin grafts (FTSGs). 10 , 11 A STSG consists of the epidermis and a portion of the dermis whilst the FTSG consists of the epidermis and the entire dermis. Traditional FTSG and STSG typically exhibit scarring and additional morbidity at the donor site. 10 However, FTSGs provide more appropriate skin colour match and texture than STSGs at the wound site. In addition, FTSGs are more durable and less sensitive to trauma than STSGs. Due to the collection of the entire dermis, FTSGs provide adnexal structures such as hair follicles to be transferred to the recipient site. 10 Adnexal structures contribute to critical skin‐associated functions including sensation, moisturization and heat loss, and are a reservoir for progenitor cells. 12 STSGs often require graft meshing to expand the coverage area and prevent the buildup of wound fluids under the graft. However, this can result in a cobblestone or ‘fishnet’ appearance of the skin thus altering the cosmetic appearance of the transplanted skin. 10 The risk factors for STSG and subsequent donor site morbidity are often underestimated. 9 Important factors to consider for donor site collections include patient comorbidities, donor site location, size of the wound, patient age, expected time to healing, risk of scarring, healthy skin availability, ability to restore complete skin architecture and expected time for rehabilitation. In an attempt to improve donor site outcomes and reduce donor site morbidity, harvesting of smaller full‐thickness autologous microcolumns (FTAM) of skin graft tissue has been proposed. Pre‐clinical animal studies utilized a collection of smaller, ‘micrografts’ that use <15%–20% of the donor site tissue mass compared to STSG donor sites using a conventional dermatome. 13 , 14 In a porcine study, microscopic skin tissue columns (MSTC) at 1.5 mm in diameter and <10 mm in length (including subcutaneous fat and adnexal structures) were prepared using a biopsy punch. 15 The MSTC were collected and transplanted directly into 3 cm diameter autologous wounds at 6.25%, 2.5% and 1% MSTC (epidermal surface area: recipient site area). Adnexal structures were observed in the MSTC‐treated wounds on Day 14 and Day 60, but not in the untreated control wounds. Wounds grafted with MSTC also had accelerated re‐epithelization and epidermal differentiation compared to the untreated controls. The ‘epithelial gap’, as defined by the distance between the advancing edges of the keratinocyte migration, was significantly less in the MSTC‐treated wounds compared to the untreated control wounds. 15 The MSTC‐treated wounds were completely re‐epithelialized by Week 2 at 2.5% and 6.25% tissue replacement. 15 In contrast, STSG lacked the dermal elements such as nerves and the adnexal structures important for establishing normal skin structure. 15 In another porcine study by Fuchs et al., 13 autologous MSTC were prepared at 0.7 mm diameter using 19 gauge needles and transplanted at 20% of the excised wound mass into a 3 cm diameter recipient site. 13 At the end of Week 1, MSTC‐treated recipient site wound beds formed ‘islands’ of epidermal tissue and by Week 2 the epidermis was restructured with differentiated stratum corneum. At Weeks 1 and 2, the untreated control wounds were more contracted and showed reduced epithelial migration that was restricted to the wound edges. In addition, the untreated control wounds were only partially re‐epithelialized (average 56%). In contrast, the MSTC‐treated wounds had significantly less contraction than the untreated controls (p < 0.05) with 99% of the wounds re‐epithelized by Week 2. 13 These results showed that transplantation of autologous MSTCs can accelerate recipient site re‐epithelization, increase collagen deposition, enhance dermal remodelling and decrease the inflammatory response compared to untreated control wounds. 13 In an in vitro study by Tam et al., 16 a conditioned medium was prepared from human full‐thickness MSTC that was obtained from skin tissue collected from abdominoplasty procedures. 16 The MSTC‐conditioned media was evaluated for the release of soluble growth factors and the ability to promote cell migration. Several soluble signalling factors were identified in the MSTC‐conditioned media, many of which are well known for their contributions to the wound healing process including three important growth factors, basic‐fibroblast growth factor, amphiregulin and vascular endothelial growth factor. 16 Proteins, cytokines and signalling factors released into the MSTC‐conditioned media were significantly increased compared to media conditioned with a comparable quantity of FTSG tissue. MSTC‐conditioned media increased human dermal fibroblast migration and proliferation. In addition, the signalling factors produced in the MSTC‐conditioned medium induced the formation of vascular tubes as demonstrated using human umbilical vein endothelial cells. 16 These results demonstrated that the MSTCs are an important source of paracrine factors in wound healing. Tam et al. 17 showed in a 3‐month‐long porcine study that hundreds of full‐thickness MSTCs approximately 700 μm in diameter could be harvested using a single‐needle harvester without scarring at the donor site. 17 These MSTC donor sites re‐epithelized within 1 week in contrast to STSG donor sites that required more than 2 weeks. The MSTC donor sites were histologically indistinguishable from normal pig skin at 7 weeks based on epidermal thickness and the number of rete ridges. Transplantation of MSTC and STSG into full‐thickness wounds significantly slowed wound contracture when compared to the untreated control wounds. For the MSTC‐treated wounds, partial re‐epithelization was observed at Week 1 and complete re‐epithelization was observed at Week 2. STSG‐treated wound sites showed immediate re‐epithelization within 1 week of treatment. The meshed STSG‐treated wounds exhibited increased scarring, uneven surfaces, and prominent folds in the epidermal and upper dermal layers. In contrast, the MSTC‐treated wound sites were smooth and uniform in topography after 5 weeks. 17 In another study by Tam et al. 12 human abdominal skin MSTCs were collected at 700 or 400 μm in diameter following elective abdominoplasties using custom designed 19 gauge or 22 gauge harvesting needles. 12 The MSTC were spread evenly on full‐thickness excised wounds created in immunodeficient mice. At 8 weeks, restoration of many key features of normal human skin tissue was observed including epidermal architecture, diverse skin cell populations, adnexal structures and sweat production from functional eccrine sweat glands. These preclinical animal study results suggest that harvesting and grafting of MSTCs is feasible and may be useful for producing anatomical skin structures with fully functional skin properties in human wounds, without long‐term donor site morbidity. 12 Traditional autologous skin grafts (STSG) are the current ‘gold standard’ for wound repair but are often associated with challenging donor site morbidity. In addition, traditional STSG requires general anaesthesia and the logistical and financial burdens involved with using operating rooms. Because of this, the use of autologous skin grafting remains limited. The Autologous Regeneration of Tissue (ART®) System can be used in an outpatient, bedside setting that limits the risks associated with accessing autologous tissue making it more accessible to patients. The ART® System is a minimally invasive, novel automated skin harvesting device designed to collect FTAM of ~0.5 mm in diameter at a donor skin site coring depth of 3.25 mm using a disposable cartridge containing 316 needles. The FTAM donor site harvesting method is based on the idea that microscopic wounds heal via tissue remodelling as opposed to scarring often associated with STSG. 14 Using a porcine full‐thickness excisional wound grafting model, we demonstrate that the ART® System can collect FTAM from donor sites and dispense them into the recipient wound sites. The results show decreased donor site morbidity compared to STSG and improved recipient site re‐epithelization with less contracture compared to the Untreated control sites. We also observed significantly less adverse events (i.e., recipient site necrosis) in FTAM recipient sites compared to STSG recipient sites. Our results confirm that the use of the ART® System provides wound site healing that is comparable to traditional STSG skin grafting methods whilst providing more rapid and superior donor site recovery. MATERIALS AND METHODS Animals procedures Eighteen female Yorkshire swine (6–8 weeks old and weighing 10–15 kg on Day 0) were used in this study. The skin of younger pigs is thinner and more pliable compared to older pigs, and also more comparable to human skin, so skin grafts were more easily obtained. 18 , 19 A 6‐week donor site and recipient wound site healing study to evaluate the healing trajectories for FTAM and STSG donor sites and for recipient wound sites for (1) FTAM, (2) STSG and (3) Untreated (recipient site only) was performed. Animal care and grafting procedures were conducted by Toxikon Laboratories (Toxikon Corporation, Bedford, Massachusetts). All studies were conducted in accordance with the US Food and Drug Administration Code of Regulations on Good Laboratory Practices for Nonclinical Laboratory Studies CFR Title 21 Part 58. Animal care and welfare standards were adhered to as governed by the Institutional Official and International Animal Care and Use Committee and Toxikon Standard Operating Procedures. All animals received humane care in compliance with the institution's guidelines and the Office for Laboratory Animal Welfare, ‘Public Health Service Policy on Humane Care and Use of Laboratory Animals’, Health Research Extension Act of 1985. Public Law 99‐158 November 20, 1985, Revised 2015. ART® System FTAM donor site harvest Animals were anaesthetised and designated donor sites for grafting were prepared aseptically. The ART® Skin Harvesting System was used to harvest animal donor site tissue and dispense it onto the recipient site as shown in Figure 1. The ART® System consists of reusable ART® Handheld Device with a disposable sleeve (Figure 1A) and the disposable cartridge containing 316 needles to harvest FTAM at 0.5 mm diameter and depth of 3.25 mm. The donor site collection area is 6.4 cm2, with roughly 10% (0.64 cm2) of this area collected with each harvest (Figure 1B). Once harvested, the ART® Handheld Device then controls the scattering of the harvested FTAM at the recipient site. The ART® System dispensing procedure of the FTAM using the ART® Handheld Device at the recipient site is shown in Figure 1C. The scattering of the FTAM at the recipient site is shown in Figure 1D. The Autologous Regeneration of Tissue (ART®) Skin Harvesting System shows (A) donor site harvesting using the ART® Handheld Device and (B) collection of the full‐thickness autologous microcolumn (FTAM) using a 316 needle cartridge within a donor site collection area of 6.4 cm2 (approximately 10% of the donor site area is collected with a single harvest). (C) Dispensing of the FTAM from the ART® Handheld Device at the recipient site and (D) scattering of a single FTAM donor site harvest from the 316 needle cartridge at the recipient site. The number of FTAM donor sites varied from 1 to 4 sites per animal for a total of 78 sites. A minimum of two complete FTAM donor site harvests were transferred to each recipient wound site. The length and number of harvesting needles are limited by safety and mechanical concerns. The needles in the ART device are about 4 mm long, which is sufficient for effective harvesting in most cases, but occasionally some microcolumns are left behind in the donor site, especially when harvesting from thicker skin. When a harvest cycle collects less than 50% of the expected microcolumns, additional harvesting cycles were performed to ensure sufficient tissue is applied to the wound site. In the current study, this occurred in six out of 78 harvest cycles. The occasional need for additional harvests is an expected outcome, and the option for additional harvests is included in the Instructions For Use of the device, therefore it is not considered to be a device failure. Three skin graft recipient site treatments were compared in this study including (1) an Untreated control group, (2) a standard STSG and (3) FTAMs harvested using the Medline ART® Skin Harvesting System (Medline Industries, LP). On Day 0, surgical dressings were changed and treatments were applied according to the following: two recipient wound sites per animal were assigned to each treatment (six per animal). The following schematic shows the location of the donor sites and recipient wound sites on the back of the pig (Figure 2). A total of 18 female juvenile pigs were prepared for the experiment in this manner. Six animals were euthanized at Week 1, Week 3 and Week 6 for tissue preparation and histology analysis. The Untreated wound sites, FTAM recipient wound sites and STSG recipient wound sites (red) were randomized for each treated animal. The FTAM and STSG donor sites (blue) were not randomized. Schematic representation of wound site locations on the pig dorsum. The full‐thickness autologous microcolumn (FTAM) and split‐thickness skin graft (STSG) donor sites are shown in blue. The FTAM, STSG and Untreated recipient wound sites were randomized and are shown in red. STSG donor site harvest Following anesthetization, the STSG‐designated donor sites were aseptically prepared. Two STSGs were harvested per animal at 1″ × 2″ and 16/1000″ deep using a dermatome (Zimmer Biomet, Warsaw, IN) from the animal's hindquarters. The STSG were trimmed to the approximate size of the recipient wound site, then meshed and expanded to cover the STSG recipient wound site. The number of STSG donor sites collected was two per animal for a total of 34 sites, with one animal excluded from the study assessment due to an upper respiratory infection. The donor sites were covered with (1) Adaptic® Non‐Adhering Dressing (3M™, St. Paul, MN), (2) a gauze square and (3) Tegaderm® Transparent Film Dressing (3M™, St. Paul, MN) in that order. Donor site dressings were replaced weekly. Recipient wound site preparation and evaluation Full‐thickness wounds are highly effusive for the first 48–72 h following creation. To prevent grafts from ‘washing off’ during grafting the recipient sites were created 2 days (Day −2) prior to the grafting procedure (Day 0). The study was designed to allow time for fluid/exudate to decrease before applying grafts and maintain a clinically relevant treatment procedure at the start of the study. Prior to surgery the animals were aseptically prepared and anaesthetised with ketamine (33 mg/kg), acepromazine (1.1 mg/kg), xylazine (2.2 mg/kg) and atropine (0.02 mg/kg), then isoflurane (0.5%) via endotracheal tube. Buprenorphine (0.02 mg/mL) was also given prior to surgery A fentanyl patch (2–3 μg/kg/h) was used for pain medication. Ceftiofur was given peri‐operatively intramuscularly as a prophylactic antibiotic. Each animal received six full‐thickness recipient site wounds approximately 4 cm in diameter with an area of approximately 12.0 cm2 (Figure 2). This wound size was selected based on a previous study by Wilcox et al. 20 that evaluated the healing of chronic ulcer sizes with an initial area of 1.0–100.0 cm2. Based on their study, we estimated that 76.7% of the wounds would have an area of 12.56 cm2 or less. Six circular wound sites were created by excision on the mid to lower back, three on each side of the spine, and separated by a minimum of 3 cm of intact skin (Figure 2) The perimeters of the wounds were marked with tattoos to monitor changes in the wound site area and to be able to delineate the initial wound size during later recipient wound site area measurements. Following surgery, the recipient wound sites were dressed with a 2 mm thick layer of DuoDerm® Hydroactive gel (ConvaTec, Reading, UK), Adaptic® Non‐Adherent Dressing and Optifoam® Adhesive Foam Dressing (Medline Industries, LP, Northfield, IL), then secured with Leukotape® (BSN Medical Inc., Charlotte, North Carolina) and covered with PetFlex™ (Andover Healthcare Inc. Salisbury, MA). Animals were treated for pain management for 6 days following surgery. Recipient wound site dressings were changed weekly. During each dressing change, saline could be applied to allow for gentle removal. The tie‐over bolster was reapplied to each wound site until Day 14 to help keep the graft in place. All recipients wound sites and donor sites were photographed during treatment throughout the study. All animals received six 12 cm2 full‐thickness excisional wounds that were grafted with either FTAM, STSG or Untreated control (without grafting). Macroscopic wound evaluation was completed during weekly dressing changes and documented with photographs. Weekly clinical (macroscopic) evaluation was performed using a scoring system for granulation, re‐epithelization, rete ridge formation, necrotic tissue and exudate. On Weeks 1, 3 and 6, six animals were euthanized for tissue collection and histology. Histological evaluation was done at terminal time points (Weeks 1, 3 and 6 post‐wounding) (n = 6 per group), and evaluated for granulation, collagen, elastin, neovascularization and inflammation. All histology sections were imaged using light microscopy and scored by a board‐certified veterinary pathologist who was blinded to the wound treatment. The surface area of a skin graft relative to the area of the recipient wound is traditionally described as the ‘expansion ratio’. This ratio is centred on the amount of epidermal tissue transferred because of its capacity to directly participate in wound re‐epithelialization, whilst the amount of dermal tissue contained in the graft is not considered. However, even though dermal cell types do not directly contribute to the composition of the epidermis, they are known to have a significant impact on keratinocytes, both through paracrine signalling and by constructing the extracellular matrix that keratinocytes rely on for attachment and migration during the re‐epithelialization process. Additionally, the amount of dermal tissue included in a skin graft has a direct influence on the degree of post‐injury contracture. 21 To conform with the standard practice in the field, in the rest of this manuscript we will describe tissue amounts based on the percent of epidermal surface area of the harvested tissue relative to the treated recipient site area, but readers should be mindful that differences in dermal tissue grafted are not reflected in this conventional nomenclature. Recipient wound site re‐epithelialization was graded using the following scale: 0% surface area of the wound (score of 0), 1%–25% surface area of the wound (score of 1), 26%–50% surface area of the wound (score of 2), 51%–75% surface area of the wound (score of 3), >75% surface area of the wound with possible thin epithelium in the wound centre (score of 4) and 100% surface area of the wound (score of 5). In this study, the amount of tissue grafted for each of the FTAM‐treated wounds was equivalent to two ART System donor site harvests of 0.64 cm2 = 1.2 cm2 or 10% of donor site to recipient wound site area of 12.0 cm2. The amount of STSG tissue grafted was 6.0 cm2 or 50% of the recipient wound site area of 12.0 cm2. Therefore, the STSG recipient wound site received a 5× greater amount of donor site tissue than the FTAM‐treated recipient wound sites as shown in Table 1. TABLE 1Grafting of donor site tissue area to recipient wound site area.Grafting systemDonor site tissue area removedRecipient wound site area graftedPercent of donor site to recipient wound site area graftedART system1.2 cm2 12 cm2 10STSG dermatome6.0 cm2 12 cm2 50Abbreviations: ART, Autologous Regeneration of Tissue; STSG, split‐thickness skin grafts. Grafting of donor site tissue area to recipient wound site area. Abbreviations: ART, Autologous Regeneration of Tissue; STSG, split‐thickness skin grafts. Macroscopic wound observations and evaluation Macroscopic wound site and donor site evaluation were completed during weekly dressing changes and documented with photographs. Wound erythema, oedema, granulation and re‐epithelization were scored using the following scale: none (0), minimal (1), slight (2), moderate (3) and marked (4). The presence or absence of exudate and the nature of its contents (blood, serous, serosanguinous, fibrinous or purulent) were recorded, as was the presence or absence of sloughing/necrotic tissue. Using the same grading scale, the condition of intact adjacent skin was evaluated in terms of erythema, oedema, pustules, ulcers, serocellular crust, scales, induration and for the presence or absence of sloughing/necrotic tissue. Additional wound characteristics, such as haemorrhaging and discolouration, were also noted. Microscopic histological analysis On Weeks 1, 3 and 6, six animals were euthanized for tissue collection and histology. These time points were selected to capture the early, middle, and late aspects of the FTAM STSG, and Untreated wound site healing. Skin biopsies of all wound and donor sites, including 1–2 cm of the surrounding normal skin margin, were collected from the centre of the wound, and fixed in 10% neutral buffered formalin. The fixed samples were paraffin‐embedded and sectioned for haematoxylin and eosin (H&E), Masson's trichrome and Verhoeff staining per manufacturers' instructions. Histopathological analysis of stained tissue sections was performed according to a pre‐defined scoring criterion. The H&E analysis included epithelial observations, re‐epithelialization, epidermal hyperplasia, rete ridges, serocellular crust, stratification, granulation and tissue response: necrosis, neovascularization, fibrosis, entrapped adipocytes and inflammation: polymorphonuclear cells, lymphocytes, plasma cells, macrophages, multinucleated cells, overall inflammation in the superficial and deep wound bed, haemorrhage, foreign debris and cysts/granulomas. Masson's trichrome staining was used for the detection of collagen and Verhoeff staining was used for detecting the presence of elastin. All histology sections were imaged and scored using light microscopy by a board‐certified veterinary pathologist who was blinded to wound treatment. Scoring for donor site and recipient site collagen was done according to the following scale: (0) no collagen, (1) scanty collagen deposition as loose, poorly organized stroma, (2) more notable collagen, majority of stroma still loose, (3) more notable collagen, majority of stroma dense and partially organized and (4) more notable collagen, with majority of stroma having appearance to native dermal collagen. Scoring for elastin was done according to the following scale: (0) no elastin, (1) scanty elastin deposition and scattered, (2) more elastin deposition, less scattered and closely arranged, (3) more elastin deposition, less scattered more closely arranged and (4) more elastin deposition, the appearance of native dermal elastin. Statistical analysis Each measurement was taken from a distinct sample. All statistical analyses were performed in Stata 17.0 (StataCorp. 2021. Statistical Software Release 17. College Station, TX. StataCorp LLC). Values are presented as mean with standard errors of the mean unless otherwise stated. Significant differences between the two groups were established by t‐test or two‐tailed Mann–Whitney test for nonparametric data. For testing significant differences amongst multiple groups, one‐way analysis of variance with Tukey's multiple comparisons test was used. Differences in proportions were tested using proportion tests based on the z‐distribution and the significance for multiple comparisons were adjusted by dividing the p‐value by the number of statistical comparisons. An electronic notebook was not used in data collection. RESULTS Donor site evaluation Macroscopic evaluation of the FTAM and STSG donor sites was performed over 6 weeks (Weeks 0–6) as shown in Figure 3. The STSG donor site erythema on Day 4, was 53% (20/38) with a score of 1–3 (minimal to moderate) compared to the FTAM donor sites that displayed less erythema at 29% (27/94) with a score of only 1 (minimal) (p = 0.0093). As shown in Figure 3, the STSG donor sites contained a greater amount of eschar at Week 1 compared to the FTAM donor sites. The STSG donor sites required up to 3 weeks to close in contrast to the FTAM donor sites that were visually undetectable. Whilst both the FTAM and STSG donor sites were closed by Week 3, FTAM donor site closure and re‐epithelization were more rapid than the STSG donor sites, reflecting the benefit of harvesting hundreds of smaller FTAM compared to collecting large sections of the epidermis/upper dermis with STSG. Representative images from Day 0 through Week 6 of split‐thickness skin graft (STSG) (top row) and full‐thickness autologous microcolumn (FTAM) (bottom row) donor sites. Compared to FTAM harvest sites, STSG had more serocellular crust, erythema, exudate and eschar at early time points and took longer to close. At Week 6, STSG donor skin appearance remains visually distinct from surrounding healthy tissue due to abnormalities in texture and colouration, a cosmetic outcome commonly observed with STSG donor sites in humans. The degree of donor site re‐epithelialization was scored by macroscopic evaluation on Day 4 and weekly from Weeks 1 through 6 and was summarized according to the percentage of sites per group with 0%–25%, 25%–75% and 75%–100% reepithelization (Table 2). On Day 4, 61% of the FTAM donor sites were 25%–75% re‐epithelialized compared to only 26% of the STSG donor sites at the same time point (p = 0.0395). At Week 1, 73% of the FTAM donor sites were 75%–100% re‐epithelialized compared to only 33% of the STSG donor sites (p = 0.0014). There was no statistical difference in donor site re‐epithelization observed between the FTAM and STSG donor sites at Week 2 and all donor sites were completely re‐epithelialized by Week 4. Taken collectively, these results demonstrate that the FTAM donor sites re‐epithelialized at a faster rate with reduced morbidity than the STSG donor sites. TABLE 2Percent of donor site re‐epithelialization.Week of evaluation% Donor site re‐epithelizationPercent of FTAM donor sitesNumber of sitesPercent of STSG donor sitesNumber of sites p‐Value a Day 40–253936/947428/380.005325–756158/942610/380.039575–10000/9400/38NSWeek 10–2577/953011/360.022025–751918/953613/36NS75–1007370/953312/360.0014Week 20–2521/5500/22NS25–75169/55184/22NS75–1008245/558218/22NSAbbreviations: FTAM, full‐thickness autologous microcolumn; NS, not significant; STSG, split‐thickness skin grafts. a Comparison of FTAM donor sites to STSG donor sites. Percent of donor site re‐epithelialization. Abbreviations: FTAM, full‐thickness autologous microcolumn; NS, not significant; STSG, split‐thickness skin grafts. Comparison of FTAM donor sites to STSG donor sites. Histological evaluation was performed at Weeks 1, 3 and 6 post‐FTAM and STSG donor site harvest (Figure 4). H&E staining demonstrated that both FTAM and STSG donor wounds healed by granulation and re‐epithelialization. However, the mechanism of tissue harvest including the collection of FTAM by the ART® System and complete removal of the epidermal and upper dermal layer with STSG resulted in histological differences between groups. Granulation tissue can be observed within each FTAM microcolumn channel at Weeks 1 and 3 but was absent by Week 6 (Figure 4A–C). At Week 6, the FTAM donor sites were indistinguishable from the surrounding tissue. In addition, the FTAM donor sites show the formation of a normal stratified epidermis with prevalent rete ridges and adnexal structures (hair follicles) within the first week after harvest and persisted through Week 6 (Figure 4A–C). In contrast, granulation tissue was observed across the entire STSG donor site and was localized to the epidermal/upper dermal layer at Weeks 1 and 3 but less apparent by Week 6 (Figure 4D–F). The entire epidermis/top superficial dermal layer is removed during STSG harvest as shown in bracketed areas (Figure 4D,E). No adnexal structures were observed at any time point during STSG donor site healing and the epidermis appears smooth with few rete ridges which are two characteristics associated with scar formation. Collectively, these results suggest that the FTAM donor sites heal faster and without any histological indications of scarring in contrast to the STSG donor sites. Histological evaluation of the full‐thickness autologous microcolumn (FTAM) and split‐thickness skin graft (STSG) donor sites. Representative images of FTAM (A–C) and STSG (D–F) donor site sections stained with haematoxylin & eosin at 1, 3 and 6 weeks post‐harvest. FTAM harvest sites are indicated by arrowheads. Boxes indicate areas shown at higher magnification (5×) in lower panels. One week post‐harvest, FTAM harvest sites appear light pink compared to dark pink adjacent non‐wounded tissue (A). By Week 3, FTAM harvest sites appear closer to surrounding skin in colouration (B). By Week 6, FTAM columns are indistinguishable from surrounding tissue, with all tissue appearing universally dark pink (C). Adnexa (hair follicles and/or glandular tissue) are observed at Week 1 within FTAM harvest columns and increased in prevalence through Week 6 (indicated with stars). Conversely, the entire epidermis/top superficial dermal layer is removed during STSG harvest, as shown by light pink staining in sections from Weeks 1 and 3 (indicated by brackets, 5× magnification, panels D and E). By Week 6, the difference in pigmentation becomes less apparent (I). Scale bars correspond with 2.5 mm and 500 μm at 1× and 5× magnification, respectively. Collagen and elastin deposition at the FTAM and STSG donor sites was evaluated by histology at Weeks 1, 3 and 6 (Figures 5 and 6). Donor site tissue maturation was assessed using collagen organization and fine elastin deposition using Masson's trichrome and Verhoeff staining, respectively. The darker blue trichrome staining is indicative of collagen maturation and higher concentrations of collagen. Mature, organized collagen is present between the FTAM microcolumn channels, as indicated by the increasing blue colouration (Figure 5A–C). One week post‐harvest, the FTAM channels appear light pink compared to blue adjacent non‐wounded tissue (Figure 5A). New collagen deposition can be observed within the FTAM donor site microcolumn channels as early as Week 1 and continues until Week 3 as shown by the light blue colouration (Figure 5B). By Week 6, the FTAM channels are no longer visible, with only mature dark blue collagen observed within the channels that are indistinguishable from the surrounding tissue (Figure 5C). Adnexal (hair follicles and/or glandular tissue) were observed at Week 1 (Figure 5A) within the FTAM microcolumn channels and increased in prevalence through Week 6. Histological evaluation of collagen and elastin at full‐thickness autologous microcolumn (FTAM) and split‐thickness skin graft (STSG) donor sites. Representative images of FTAM (A–F) and STSG (G–L) donor wound sections stained with Masson's trichrome (left panels) or Verhoeff (right panels) at 1, 3 and 6‐weeks post‐harvest. FTAM harvest sites are indicated by arrowheads. Boxes indicate areas shown at higher magnification (5× trichrome and 40× Verhoeff) in lower panels. In Masson's trichrome‐stained sections, collagen appears blue with a darker colour associated with thicker collagen fibres/increased maturation. One week post‐harvest, FTAM harvest sites appear light pink compared to blue adjacent non‐wounded tissue (A). By Week 3, FTAM harvest columns appear blue, indicating the presence of collagen (B). By Week 6, FTAM columns are indistinguishable from surrounding tissue, with all tissue appearing universally dark blue (C). Adnexa (hair follicles and/or glandular tissue) are observed at Week 1 within FTAM harvest columns and increased in prevalence through Week 6 (indicated with stars). Conversely, the entire epidermis/top superficial dermal layer is removed during STSG harvest, as shown by pink staining in sections from Weeks 1 and 3 (indicated by brackets, 5× magnification, panels G and H). By Week 6, wounds are not fully healed, as the collagen stain remains light blue (I, bracket). In Verhoeff‐stained tissues, thicker/mature collagen bundles appear dark pink; less mature collagen appears light pink. Elastin appears as fine dark lines (arrows). Positive elastin staining was observed beginning at Week 1 in FTAM harvest sites (D) and Week 3 in STSG harvest sites (K) and increased in prevalence over time. Scale bars correspond with 2.5 mm, 500 μm, and 50 μm at 1×, 5× and 40× magnification, respectively. Donor site collagen and elastin. Donor sites were stained with Masson's trichome and Verhoeff to grade collagen (A) and elastin (B) deposition and organization, respectively. The percentage of donor sites with majority of stroma having a similar appearance of native dermal collagen (Score 4) (A) and scanty and scattered elastin deposition (Score 1) (B) in the superficial dermis is shown. The percentage of sites with notable collagen content (Score 4) and positively staining for elastin was higher and occurred sooner in full‐thickness autologous microcolumn (FTAM) donors when compared to split‐thickness skin graft (STSG) donors. Intergroup comparisons within the same time point were performed using proportion z‐tests where *p < 0.05 was considered statistically significantly different (n = 13–39 per group per week). The progress of healing and collagen deposition was different at the STSG donor sites. Collagen deposition was sparsely observed in the dermal layer of the STSG donor sites at Week 1 (Figure 5G) and was less organized than in the FTAM donor sites at Week 3 (Figure 5H). By Week 6, both FTAM and STSG dermal stroma collagen were observed (Figure 5C,I). However, at Week 6, the percentage of donor sites that were positive for mature collagen was significantly greater (p = 0.0008) for the FTAM donor sites than for the STSG donor sites at 100% versus 62%, respectively as shown in Figure 6. Positive elastin staining was observed beginning at Week 1 in the FTAM donor sites (Figure 5D) and at Week 3 in the STSG donor sites (Figure 5K). Both the FTAM and STSG donor sites had an increase in the prevalence of elastin from Week 3 to Week 6 (Figure 5F,L). However, at Week 6, the percentage of donor sites that were positive for elastin was significantly greater (p = 0.0115) for the FTAM donor sites than for STSG donor sites at 90% versus 46%, respectively (Figure 6). Fine elastin fibre deposition can be seen scattered at the FTAM donor sites at Weeks 1, 3 and 6 (Figure 5D–F) and at the STSG donor sites at Weeks 3 and 6 (Figure 5K,L). The increase in the rate of collagen and elastin deposition at the FTAM donor sites is representative of more rapid and progressive donor site healing compared to the STSG donor sites. Overall, a greater percentage of the FTAM donor sites contained mature collagen and elastin compared to the STSG donor sites at Weeks 1, 3 and 6, which can especially be seen in the FTAM donor site microcolumn channels (Figure 5A–C). As shown in Figure 6, the percentage of FTAM donor sites positively stained for collagen and elastin consistently increased from Weeks 1 through 6. Nearly 90% of the FTAM donor sites contained mature collagen and elastin by Week 6. In contrast, mature collagen at the STSG donor sites was present only at Week 6 and elastin was present at Weeks 3 and 6. At Week 6, a greater percentage of FTAM donor sites displayed superficial dermis with the majority of stroma having a similar appearance to native dermal collagen (score of 4) with a greater percentage of donor sites positively staining for elastin. Based on collagen and elastin deposition, these results suggest that the FTAM donor sites are healing and maturing at a faster rate than the STSG donor sites. The donor sites were also evaluated macroscopically for wound drainage and for exudate that was characterized as serosanguinous (SS), serous (S), blood (B), fibrinous (F) or negative (N) from Day 4 to Week 4. (Figure 7) At Day 4, 87% of the FTAM donor sites were negative for exudate compared to 39% for the STSG donor sites. At Week 1, 96% of the FTAM donor sites were negative for exudate compared to 53% for the STSG donor sites. The STSG donor sites also had a greater percentage of donor sites with S and SS exudate at Weeks 1 and 2 compared to the FTAM donor sites. Donor wound site fluid was observed beginning on Day 4 and then weekly (Weeks 1–4). No fluid was observed after 4 weeks. Exudate was scored as N (negative), serous (S), serosanguinous (SS), blood (B) or fibrinous (F). Data are shown as the percentage of full‐thickness autologous microcolumn (FTAM) and split‐thickness skin graft (STSG) donor sites with each exudate characteristic. Note a few data points are missing from the analysis at Week 1 and Week 2 for the STSG donor sites. Donor site erythema was also evaluated macroscopically from Day 4 to Week 6. Scoring for erythema was (0) none, (1) minimal, (2) slight, (3) moderate and (4) marked. On Day 4, 53% (20/38) of the STSG donor sites received a score of 1–3 (minimal to moderate) as compared to the FTAM donor sites at 29% (27/94), which only received a score of 1 (minimal) which was significantly lower (p = 0.0093). At Week 1, 28% of the STSG donor sites had a score of 1–3 as compared to 17% of the FTAM donor sites with a score of 1–3. At Week 2, the total erythema scoring for both sites was 0–1. Overall donor site inflammation and fibrosis decreased during the study. Donor site fibrosis as defined as narrow to extensive bands was similar for both the FTAM and STSG, decreasing between Week 1 and Week 3 from 67% to 8% of FTAM donor sites and from 50% to 19% of STSG donor sites. Donor site neovascularization as a percentage of the donor sites counted was similar between the FTAM and the STSG donor sites with both donor sites having some degree of neovascularization at Week 1. However, at Week 6 neovascularization was more prevalent in the STSG donor sites compared with the FTAM donor sites (77% vs. 30%, respectively). These results are consistent with the neovascularization process for STSG however, the FTAM donor sites had fewer blood vessels. The relatively small size of the FTAM donor sites may be a contributor to the lesser extent of neovascularization in these sites. Since the radius of each individual FTAM donor site is only about 250 μm, a large portion of the donor site volume is within the oxygen diffusion limit (typically about 100–200 μm) from neighbouring uninjured tissue, which could lead to a lower demand for angiogenesis in the wound bed. Recipient wound site evaluation Full‐thickness excisional wounds were evaluated macroscopically before and after FTAM and STSG grafting and weekly throughout the study. Two representative FTAM recipient sites and one Untreated control site are shown in Figure 8. The FTAM recipient wound sites are shown at the time of recipient wound site creation (Day −2) in Figure 8A, and immediately following FTAM deposition (Day 0) in Figure 8B and at Day 6 after FTAM deposition in Figure 8C. Distinct ‘epithelial islands’ developed within the FTAM recipient site wound beds at Day 6 and continued throughout the 6‐week time period (Figure 9) along with re‐epithelization and wound closure. In contrast, the Untreated control sites do not show ‘epithelial islands’ at this stage of wound healing or throughout the 6‐week study. Representative photographs of two recipient wounds 2 days before (A), immediately following (B) and 6 days post‐full‐thickness autologous microcolumn (FTAM) deposition (C). Epithelial islands can be seen on Day 6 as the light‐coloured substance in the middle of the wound beds. On casual observation these may appear similar to wound sloughing or purulent material, but they consist of epidermal outgrowth derived from the FTAMs (see histologic images in Figure 10). These epithelial islands are not seen in Untreated controls (last row). Representative recipient sites from Day 0 (pre‐ and post‐grafting) until Week 6 for split‐thickness skin graft (STSG) recipient sites (top row), full‐thickness autologous microcolumn (FTAM) recipient sites (middle row) and Untreated control sites (bottom row). Tattoos were used to monitor changes in wound size due to animal growth and assess contracture. Note the presence of a linear scar and incomplete wound closure of Untreated sites at Week 6 compared to STSG and FTAM recipient sites, which healed by re‐epithelialization and are completely closed. Representative recipient sites from Day 0 (pre‐and post‐grafting) until Week 6 for STSG recipient sites are shown in (Figure 9‐top row), FTAM (Figure 9‐middle row), and Untreated control sites (Figure 9‐bottom row) All recipient sites were approximately 4 cm in diameter with an initial area of approximately 12.0 cm2. As shown in Figure 9A,B, the STSGs were harvested, trimmed, stretched to cover the STSG recipient site, and sutured into place. The meshed pattern covering the STSG recipient wound site can be seen in Figure 9B. Non‐grafted wounds served as Untreated controls and were covered with a dressing but did not receive a tissue graft (Figure 9‐bottom row). Differences in wound contracture, re‐epithelialization and healing progression were grossly apparent between groups. Untreated controls heal by rapid contracture, which is typical with these types of wounds in swine and most animal models, but not humans. The presence of epithelium, whether by STSG or by transfer of full‐thickness tissue microcolumns, is known to inhibit contracture, and to promote rapid re‐epithelialization and the development of a normal epidermis. 17 Macroscopic (clinical) observation of Untreated controls at Week 6 shows contracture to a linear scar with the centre of some wounds remaining open (Figure 9‐bottom row) whereas all STSG and FTAM treated wounds were closed/re‐epithelialized by Weeks 4 and 5, respectively (Figure 9‐top and middle rows). The mean time to recipient wound site closure was 2.4 weeks (STSG, n = 19), 3.3 weeks (FTAM, n = 23) and 4.1 weeks (Untreated control, n = 14) shown in Figure 10. Individual terminal time points are shown for only those wound sites that were completely closed. Time to wound closure was statistically different between the three groups (p < 0.05) indicating that wound closure and re‐epithelization were occurring at different rates. As shown in Figure 10, a significant difference was observed between the FTAM and STSG sites compared to Untreated control sites (p < 0.05). A significant difference was also observed between the FTAM sites compared to STSG sites (p < 0.05). Whilst the STSG wound sites closed faster, the undesirable cosmetic outcome of a meshed creasing pattern (i.e., cobblestone appearance) that often occurs after STSG in humans is evident in these wounds but not observed in FTAM‐treated wounds, where re‐epithelialization resulted from the expansion of epithelial islands throughout the wound beds and from wound edges with no undesirable cosmetic outcomes observed. Time to wound closure for split‐thickness skin graft (STSG), full‐thickness autologous microcolumn (FTAM) and Untreated control recipient sites. Data are presented as the mean ± SEM and was 4.1 weeks (Untreated control), 2.4 weeks (STSG) and 3.3 weeks (FTAM). Individual wound closure data points are represented as triangles on the graphs. A significant difference was observed for FTAM and STSG sites compared to Untreated control sites (*p < 0.05). A significant difference was also observed for FTAM sites compared to STSG (# p < 0.05). Statistical evaluation was done by one‐way analysis of variance with Tukey's multiple comparison post‐test. Note those wounds that were not completely closed by each terminal time‐point are excluded from the graph. The percentage of recipient wounds with 100% re‐epithelialization was scored by macroscopic evaluation (Figure 11). Complete re‐epithelialization was observed at Week 2 in 8% of the Untreated control recipient sites, 26% of the FTAM recipient sites and 59% of the STSG recipient sites and continued to increase through Week 6 for all recipient sites. There was a significant difference at Week 3 for the STSG recipient sites compared to the Untreated control sites (p < 0.05) and at Week 4 comparing FTAM sites to the STSG sites (p < 0.05). All STSG recipient sites were completely re‐epithelialized by Week 4 and FTAM recipient sites were completely re‐epithelialized by Week 5. Conversely, only 75% of the Untreated control sites were completely re‐epithelialized by Week 6. The percentage of recipient sites with complete re‐epithelialization was significantly greater (p < 0.05) in both the FTAM and the STSG recipient sites when compared to the Untreated controls at Weeks 5 and 6 (Figure 11). Re‐epithelization of recipient sites was scored by macroscopic evaluation and is presented as the percentage of wounds with complete (100%) re‐epithelialization at Week 1 to Week 6. Intergroup comparisons within the same time point were performed using proportion z‐tests where *p < 0.05 compared to Untreated control and # p < 0.05 was compared to split‐thickness skin graft (STSG) recipient sites (n = 11–36 per group). The recipient sites were also evaluated using histological analyses as shown in Figure 12. All recipient sites healed through granulation and re‐epithelialization, as shown in the H&E images for FTAM (Figure 12A–C), STSG (Figure 12G–I), and Untreated control recipient sites (Figure 12M–O). One‐week post‐wounding, FTAM recipient site re‐epithelialization occurred at wound margins and within the wound bed via the formation of ‘epithelial islands’ (see Figure 8). At Week 1, FTAM recipient sites were partially re‐epithelialized with pronounced epithelial islands throughout the wound bed (Figure 12A,D). Both FTAM and STSG recipient sites developed rete ridges by Week 1 that persisted to Week 6, when Untreated control sites were characterized by effacement of rete ridges. Re‐epithelialization was also observed in STSG recipient sites by Week 1 but was not present in the Untreated control sites until Week 3. Rete ridges were present in the FTAM and STSG recipient sites by Week 1 but not in the Untreated control sites at any time point. Prominent folds were observed in the epidermal and upper dermal layers in STSG recipient wounds which is characteristic of the undesirable cosmetic outcome of an uneven surface and meshed creasing pattern associated with STSG grafting in humans. Recipient wound histology. Representative images of haematoxylin & eosin‐stained sections from full‐thickness autologous microcolumn (FTAM) (A–C), split‐thickness skin graft (STSG) (G–I) and Untreated (M–O) recipient wounds and Masson's trichrome‐stained sections from FTAM (D–F), STSG (J–L) and Untreated (P–R) wounds and at 1, 3 and 6‐weeks post‐treatment. Wound margins are indicated by arrowheads. Boxes indicate areas shown at 5× magnification. One week post‐wounding, FTAM‐recipients were partially re‐epithelialized with pronounced epithelial islands throughout the wound bed (A, D indicated by stars). By week 6, complete re‐epithelialization was seen in all groups. Both FTAM and STSG‐recipient wounds developed rete ridges by Week 1 (arrows) that persisted to Week 6 when untreated sites were characterized by effacement of rete ridges. The characteristic uneven surface of meshed STSGs was evident as prominent folds in the epidermal and upper dermal layers, remaining through Week 6 (I, L, indicated with ovals). The scale bar corresponds to 2.5 mm (1× magnification, top panels) and 500 μm (5× magnification, bottom panels). Additional histological analyses using Masson's trichrome staining were performed to assess collagen content and wound maturation. Collagen‐positive tissue (with slight variation) was observed at all recipient sites beginning at Week 1, as shown in Figure 12; FTAM (Figure 12D–F), STSG (Figure 12J–L), and Untreated sites (Figure 12P–R). Only scant and loose collagen was detected in the FTAM recipient sites and the Untreated control sites at Week 1, but more than half of the STSG recipient wounds were positive for collagen (Figure 12J). The degree of wound maturation, based on the intensity of blue colouration and collagen organization, was slightly increased at the STSG recipient sites, compared to FTAM recipient sites and Untreated controls. By Week 3, STSG recipient sites (Figure 12K) had slightly more organized collagen than FTAM recipient sites, which in turn, had more organized collagen than the Untreated control sites. By Week 3, the percentage of recipient sites with notable collagen as reflected by a score of 2 or above was 100% of the STSG recipient sites, 73% of the FTAM recipient sites and only 27% of the Untreated sites. By Week 6, increased collagen was observed in STSG and FTAM recipient sites which can be visualized by the deeper blue staining (Figure 12F,L,R). At Week 6, 100% of the FTAM and STSG recipient sites and 93% of Untreated control sites contained notable collagen. The percentage of recipient sites with notable collagen content was higher and occurred sooner in STSG recipient sites and was significantly different from the FTAM and Untreated controls (p < 0.05). The recipient wound sites were evaluated macroscopically for wound drainage and the presence of exudate as shown in Figure 13, at Day 0 and continuing through Week 4. Exudate was characterized as follows: serosanguinous (SS), serous (S), blood (B), fibrinous (F), purulent (P) or negative (N). On Day 0, SS and S exudate was present in 64% of STSG recipient sites, 81% of FTAM recipient sites and 69% of Untreated Control sites. On Week 1, the total exudate at the FTAM recipient sites (86%) and Untreated Control sites (89%) exceeded that of the STSG recipient sites (39%). However, on Week 2, there was no difference in total exudate between the STSG and the FTAM recipient sites. Conversely, 38% and 29% of the Untreated recipient wound sites still contained exudate at Weeks 2 and 3, respectively. The exudate was minimal in both STSG and FTAM‐recipient wounds by Week 3 and absent at Week 4. Recipient wound site fluid was observed beginning on Day 4 and then weekly (Weeks 1–4). No fluid was observed after 4 weeks. Exudate was scored as N (negative), serous (S), serosanguinous (SS), blood (B), purulent (P) or fibrinous (F). Data are shown as the percentage of full‐thickness autologous microcolumn (FTAM), split‐thickness skin graft (STSG) and Untreated recipient sites with each exudate characteristic. The STSG, FTAM and Untreated recipient wound sites with oedema and erythema were evaluated at Weeks 1–6 (Table 3). Oedema peaked in the FTAM recipient sites and Untreated Control sites at Week 1 at 47% and 31%, respectively. Oedema peaked at 30% in the STSG recipient sites at Week 2. Erythema peaked in the FTAM recipient sites and Untreated Control sites at Week 1 at 31% and 25%, respectively. Erythema peaked in the STSG recipient sites at Week 2 at 48%. No oedema was observed beyond Week 3. No erythema was observed beyond Week 4. TABLE 3Percent of recipient sites with oedema and erythema.ObservationTime pointSTSG sitesFTAM sitesUntreated controlOedemaDay 06%3%8%Week 123%47%31%Week 230%17%25%Week 39%4%13%ErythemaDay 00%0%0%Week 140%31%25%Week 248%17%25%Week 327%13%25%Week 417%8%17%Abbreviations: FTAM, full‐thickness autologous microcolumn; STSG, split‐thickness skin grafts. Percent of recipient sites with oedema and erythema. Abbreviations: FTAM, full‐thickness autologous microcolumn; STSG, split‐thickness skin grafts. The infiltration of lymphocytes, macrophages and polymorphonuclear cells (PMCs) at the recipient wound sites was also evaluated for the presence of wound site inflammation. Overall, for FTAM recipient sites, STSG recipient sites and Untreated Control sites, 60%–80% had lymphocyte infiltration at Weeks 1 and 3. Macrophages were observed for all wound sites decreasing between Weeks 1 and 6, from 85% to 0% (FTAM sites), 62% to 8% (STSG sites) and 83% to 13% (Untreated sites). The PMCs decreased between Week 1 and Week 6 from 100% to 0% (FTAM sites), 77% to 17% (STSG sites) and 100% to 7% (Untreated Control sites). Overall, cellular infiltration and wound site inflammation decreased for all recipient wound sites during the study, with a slight increase in inflammation at the Untreated Control sites compared to the FTAM recipient wound sites at Week 6. Neovascularization was similar for all three types of recipient wound sites between Week 1 and Week 6 ranging from 80% to 100% of the FTAM recipient sites and Untreated control sites to 67%–100% of the STSG recipient sites. The percentage of recipient wound sites with adverse events, including necrotic tissue and sloughing, differed between groups (Table 4). At Week 1, 72% of the STSG recipient sites and 17% of the FTAM recipient sites exhibited necrotic tissue (p < 0.05). Out of the STSG recipient sites with necrotic tissue, 19% were moderate or marked, whereas none of the FTAM recipient sites were moderate or marked. By Week 2, 39% of STSG recipient sites had adverse events whereas none were observed in FTAM recipient wounds. Overall, the FTAM recipient sites displayed less sloughing and necrotic tissue than the STSG recipient sites. TABLE 4Percent of recipient sites with necrotic tissue/sloughing.Week of evaluationUntreated controlFTAM sitesSTSG sites p‐Value a Day 0000NSWeek 11417720.0001Week 200390.0006Week 31349NSWeek 4880NSWeek 5800NSWeek 6000NSAbbreviations: FTAM, full‐thickness autologous microcolumn; NS, not significant; STSG, split‐thickness skin grafts. a Comparison of Autologous Regeneration of Tissue to STSG wounds. Percent of recipient sites with necrotic tissue/sloughing. Abbreviations: FTAM, full‐thickness autologous microcolumn; NS, not significant; STSG, split‐thickness skin grafts. Comparison of Autologous Regeneration of Tissue to STSG wounds. DISCUSSION We describe the application of the ART® System, a novel skin harvesting device, used for the collection of autologous full‐thickness micrografts and the treatment of full‐thickness excisional wounds in a porcine model. The FTAM donor sites showed excellent closure as early as Week 1 which was confirmed by re‐epithelization, collagen formation and elastin deposition. In contrast, the conventional STSG donor sites required >2 weeks to show signs of healing and re‐epithelization. As early as Week 1, 73% of FTAM donor sites reached 75%–100% re‐epithelization which was significantly greater compared to re‐epithelization in only 33% of STSG donor sites (p > 0.05). By histological assessment, FTAM donor sites were completely re‐epithelized by Week 3 with adnexal structures and rete ridge formation. In contrast, STSG donor sites showed decreased adnexal structures and rete ridge formation (indicative of scarring). The FTAM donor site microcolumn channels contained more mature, organized collagen and increased elastin deposition at Weeks 1, 3 and 6 compared to the STSG donor sites. The FTAM donor site microcolumn channels were not visible at Week 6, having been replaced by well‐organized collagen and fine elastin fibres. The STSG donor sites did not contain substantial levels of collagen or elastin until Week 6. Collectively, these results indicate that FTAM donor sites heal faster and with better restoration of native skin architecture than STSG donor sites. Several investigators have reported on the donor site morbidities and increased scarring that is associated with traditional STSG donor sites. 7 , 8 , 9 Using a single‐needle prototype device, Tam et al., 17 observed reduced morbidity and complete re‐epithelization within 1 week following full‐thickness MSTCs collections. In contrast, STSG donor sites re‐epithelized after 2 weeks and retained scar‐like characteristics throughout the 3‐month study. The MSTC donor sites were histologically indistinguishable from surrounding normal porcine skin by 7 weeks. Similarly, we observed reduced donor site morbidity and 73% of FTAM donor sites reached 75%–100% re‐epithelization within 1 week of FTAM collection. In addition, we observed greater rete ridge formation in FTAM donor sites compared to STSG donor sites, an observation consistent with other reports of greater presence of scarring at the STSG donor sites and less scarring at the MSTC donor site. 13 , 17 As expected, the STSG recipient sites showed faster re‐epithelization, granulation and collagen deposition. There were significant differences in the degree of wound contraction between all three experimental groups, with the Untreated controls showing the highest degree of contraction, FTAM recipient sites contracting less and STSG recipient sites contracting the least. This order is consistent with the comparative re‐epithelialization rates between the three groups, as wound contracture is typically inversely related to the degree of re‐epithelialization. Time to wound closure was 2.4 weeks for STSG recipient sites, 3.3 weeks for FTAM recipient sites and 4.1 weeks for Untreated controls. The increased contracture but slower rate of re‐epithelialization for the FTAM recipient sites is likely due to only 10% donor tissue grafted at the FTAM recipient sites compared to 50% donor site tissue grafted at the STSG recipient site. Slower re‐epithelialization (compared to STSG) at early post‐treatment time points has similarly been reported in human chronic wounds treated with minced skin grafts, however, the same study also reported that long‐term functional outcomes, including skin pigmentation, itching and scarring, were all superior in the group treated with minced micrografts (MSG). 22 MSTC treatments have been shown to provide similar benefits as MSG. 12 , 17 An additional porcine wound healing study demonstrated that MSTC‐treated wounds had accelerated re‐epithelization and reduced contraction compared to Untreated control wounds. 13 At Weeks 1 and 2, the Untreated control sites were more contracted and showed reduced epithelial cell migration that was restricted to the wound edges. As a result, the Untreated control wounds were only partially re‐epithelialized (average 56%). In contrast, the MSTC‐treated wounds had significantly less contracture than the controls (p < 0.05) and an overall average of 99% of the wounds were re‐epithelized by Week 2. 13 We report similar findings in our study, where the Untreated control sites primarily healed by contracture with re‐epithelization restricted to wound edges and FTAM and STSG recipient sites healing by re‐epithelizion with complete wound closure observed at 5 weeks. In skin grafting, the ratio between the area of donor tissue versus the area of the recipient wound site is often referred to as the ‘expansion ratio’ which reflects the percentage of epidermal donor skin area transferred to the wound area. The lower percent of donor site epidermal tissue transferred can be beneficial for reducing donor site morbidity and is especially important in treating large area wounds, such as burn wounds, where donor site availability becomes more limited. Conventional STSGs are typically restricted to 50%–33% donor site tissue area to recipient site area. We have demonstrated that dispensing smaller FTAM that were 0.5 mm diameter × 3.25 mm length at 10% of the wound site area is sufficient for promoting complete wound site re‐epithelization at 5 weeks. Our results are consistent with the findings of Nuutila et al. 23 using smaller minced skin grafts in a porcine burn wound model where wound site re‐epithelization was complete at 4 weeks at 10% of the wound area. 23 In a variety of porcine studies, minced STSG, dermal pixel grafts and 1.5 mm MSTC have been evaluated at different ratios and percent donor site to wound area of 0.2%–10%. 15 , 23 , 24 , 25 In these deep partial‐thickness burns and full‐thickness wound healing studies, it took up to 2–4 weeks to completely re‐epithelize the wound site depending on the amount of grafted tissue. We show the effectiveness of applying FTAM at the equivalent of 10% donor tissue to the wound area, but it is likely that the FTAM donor site tissue could also be applied at lower amounts, if necessary. Furthermore, in human skin ulcer studies, the ratio was previously shown to be 11% for minced tissue compared to 33% for conventional STSG. 22 At 33% for STSG the wounds re‐epithelized at 4 weeks whilst at 11% minced tissue the wounds were re‐epithelized at 8 weeks. Human burn studies demonstrated that donor‐site skin tissue used in a spray can be significantly reduced by 32% compared to STSG (p < 0.001). 26 Using 1 cm2 of donor site tissue in an enzymatically prepared spray suspension was sufficient to treat mixed‐depth burn wound sites up to 80 cm2. Our results also suggest that ART® System harvested FTAM may have the potential to provide sufficient wound site re‐epithelization for larger‐sized wounds since rapid wound closure was observed with only 10% of the recipient wound site area. CONCLUSION Using a porcine full‐thickness excisional wound grafting model we demonstrated that use of a novel skin harvesting device, the ART® System, can be used for the collection of autologous FTAM for the treatment of wounds. Using the ART® System we observed no long‐term donor site morbidity. In contrast, STSG donor site morbidity was observed, including increased erythema and exudate at Day 4 and Week 1 and eschar at Week 3. Additionally, donor site re‐epithelization, collagen and elastin content, the presence of adnexal structures and rete ridge formation occurred much earlier in FTAM donor sites compared to STSG donor sites. Following FTAM donor site harvesting, we observed rapid re‐epithelization by Day 4, mature collagen and elastin deposition by Week 1, adnexal structures and rete ridge formation by Week 3. Whilst FTAM recipient site healing was slower compared to STSG recipient wounds, this was as expected, since 5× less graft tissue was transfer to FTAM recipient wounds. Importantly, the STSG recipient sites had more necrotic tissue at early time points and healed wounds displayed the undesirable meshed, cobblestone appearance, as often observed with STSG grafts in humans. Complete FTAM recipient site re‐epithelization occurred at 5 weeks as a result of microcolumn ‘epithelial islands’ growing from within the wound bed and from normal re‐epithelialization from wound edges. The FTAMs can augment recipient wound site healing using less donor site tissue than STSG due to ‘epithelial island’ expansion that limits contracture without the development of the meshed, cobblestone pattern typically seen with STSG wounds. Both graft types were favourable to Untreated control sites which healed by contracture down to a linear scar with the centre of some wounds remaining open at the end of the 6‐week study. The ART® System is a minimally invasive skin harvesting device that shows promise for use in human clinical studies. Using a porcine full‐thickness excisional wound grafting model our results show that the FTAM donor sites heal faster and with less donor site morbidity than STSG. Our preliminary results in a porcine wound model suggest that the ART® System can provide a viable alternative to STSG in a clinical setting. There are many clinical and practical advantages of using the ART® System over conventional STSG. ART® System donor sites have reduced morbidity and accelerated healing and grafting procedures can be performed in an outpatient setting with local anaesthesia versus an inpatient procedure requiring general anaesthesia for STSG grafts, thus reducing the length of hospital stays, economic burden and patient risk and increasing patient accessibility. LIMITATIONS The main study limitation is the use of a porcine model to compare grafting strategies intended for clinical use. Whilst the porcine wound healing model is the most similar animal model to humans available for research purposes there are some key differences. Therefore, this animal study may not perfectly represent the characteristics of donor and recipient wound healing in humans. Moreover, in the clinical setting, the ART® System is unlikely to be used on clean surgical excision wounds, with no underlying pathology, as was used in this study. FUNDING INFORMATION Medline Industries, LP supplied the ART® System and provided funding for this animal study. CONFLICT OF INTEREST STATEMENT Joshua Tam participated in this study as a consultant for Medline Industries, LP. Lisa Nicholson, Brenda Curtis, Tyler Max, Brian Prevish, Gregory Manista and Stephen Smith are employees of Medline Industries, LP. Smith S, Curtis B, Nicholson L, et al. Application of a minimally invasive full‐thickness autologous microcolumn skin harvesting device for donor site tissue collection and augmenting wound healing in a porcine wound model. Int Wound J. 2024;21(12):e70094. doi: 10.1111/iwj.70094 DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.